Hybio Pharmaceutical Co.,Ltd. (300199.SZ) has announced the receipt of an official acceptance notice from China's National Medical Products Administration for its clinical trial application of the HY3003 injection.

HY3003 represents a novel GLP-1R/GIPR/GCGR triple receptor agonist developed through a partnership between Hybio Pharmaceutical Co.,Ltd. and Shenzhen Carbon Cloud Intelligent Peptide Drug Technology Co., Ltd. The molecule was identified using an innovative approach that combines artificial intelligence with peptide chip technology, with Hybio Pharmaceutical Co.,Ltd. taking responsibility for preclinical studies, investigational new drug filing, and subsequent clinical development.

The investigational therapy targets weight reduction and related metabolic conditions, positioning it as a significant pipeline asset in the company's metabolic disease portfolio. The current filing covers the injectable formulation intended for the weight loss indication.

This project exemplifies the strategic collaboration between Hybio Pharmaceutical Co.,Ltd. and its partner in the AI-driven peptide discovery space. The partnership leverages complementary strengths: the collaborator brings proprietary silicon-based peptide chip technology and AI algorithms for molecular screening, while Hybio Pharmaceutical Co.,Ltd. contributes its extensive experience in peptide synthesis, purification, formulation development, and clinical translation. Together, the companies have established an integrated pathway spanning AI-assisted peptide discovery through to industrial-scale development and regulatory approval.